Lauren Averett Byers, MD, on ABBV-706 in Relapsed or Refractory SCLC

June 03, 2026 By The ASCO Post Staff

Lauren Averett Byers, MD, of The University of Texas MD Anderson Cancer Center, describes data on ABBV-706—an investigational antibody-drug conjugate targeting SEZ6—alone or in combination with the anti–PD-1 monoclonal antibody budigalimab in patients with relapsed or refractory small cell lung cancer (SCLC) (Abstract 8008). 

Related Content